Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta ...

Intercept Pharmaceuticals, Inventiva, Madrigal, Merck, Novartis, Novo Nordisk, Pfizer, Poxel, Salix Pharmaceuticals, Siemens, Sun Pharmaceutical Industries Inc, Terns and Valeant Pharmaceuticals and a ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

Madrigal Pharmaceuticals Inc. Four Tower Bridge 200 Barr Harbor Drive Suite 200 West Conshohocken, Pennsylvania 19428 Phone1 267 824-2827 IndustryPharmaceuticals SectorHealth Care/Life Sciences ...